Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7911-7920 Newer>

The Motley Fool September 30, 2011 David Williamson	This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more.
The Motley Fool September 30, 2011 David Williamson	4 Health-Care Stocks Worth Watching Four companies our analysts are watching ahead of earnings.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool September 30, 2011 Brian Orelli	Pfizer's Fungus Failure A combination treatment doesn't work.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
The Motley Fool September 29, 2011 Brian Orelli	Investors Guide to the New PDUFA Changes are in the air for drugmakers and the FDA.
The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
<Older 7911-7920 Newer> Return to current articles.